These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22996635)

  • 1. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
    Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
    Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
    Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune mechanism of the antitumor effects generated by bortezomib.
    Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
    J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
    Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
    Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A; Asano T; Ito K; Asano T
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
    Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
    Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
    J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Valentiner U; Haane C; Nehmann N; Schumacher U
    Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.